Federal Judge Dismisses Antitrust Case Against Bristol Myers’ Celgene Over Blood-Cancer Drug Patents

A New York federal judge has dismissed an antitrust class action against Bristol Myers Squibb’s Celgene subsidiary. The case accused Celgene of fraudulently securing patents and pursuing “sham” infringement lawsuits to delay generic versions of its blood-cancer drug, Pomalyst. The plaintiffs, comprising indirect drug buyers, were deemed to lack standing and failed to adequately allege fraudulent behavior, leading to the suit’s conclusion in favor of Bristol Myers. For more detailed information, you can access the full report on Law360.